Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Executive Summary
Company starts 'a new chapter' with the first approval out of its biosimilar pipeline, which happens to be for the biggest drug in the world.
You may also be interested in...
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
New AbbVie Guidance Sets High Bar For Post-Humira Pipeline
AbbVie boosted its revenue guidance, increasing its longer-term Humira forecast from $18bn in 2020 to $21bn, raising the bar for drugs that will make up for revenue lost when biosimilar competition arrives in five years.
Setback For AbbVie’s Humira As English Court Decision Clears Way For Biosimilars
Samsung Bioepis and Fujifilm Kyowa Kirin Biologics have won a patent battle that should allow them to launch their biosimilar versions of AbbVie’s Humira in the UK and may also have implications for other companies wanting to clear away legal uncertainties.
Need a specific report? 1000+ reports available
Buy Reports